CAS 1599440-13-7
:Deruxtecan analog
Description:
Deruxtecan analog, identified by the CAS number 1599440-13-7, is a synthetic compound primarily studied for its potential application in cancer therapy. It belongs to a class of drugs known as antibody-drug conjugates (ADCs), which combine a targeted antibody with a cytotoxic drug to selectively deliver the therapeutic agent to cancer cells while minimizing damage to healthy tissues. The structure of Deruxtecan analog features a linker that connects the cytotoxic agent to the antibody, enhancing its stability and efficacy. This compound is characterized by its ability to penetrate tumor cells and release the cytotoxic agent intracellularly, leading to cell death. Its mechanism of action typically involves the inhibition of DNA synthesis, making it effective against various malignancies. Additionally, Deruxtecan analog is under investigation for its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion, which are crucial for determining its therapeutic potential and safety profile in clinical settings.
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 6 products.
Deruxtecan
CAS:Deruxtecan is an ADC drug-linker conjugate composed of a derivative of DX-8951 (DXd) and a maleimide-GGFG peptide linker used in the synthesis of DS-8201 and U3-1402.Cost-effective and quality-assured.Formula:C52H56FN9O13Purity:98.15% - 98.20%Color and Shape:SolidMolecular weight:1034.05Deruxtecan
CAS:<p>an ADC drug-linker conjugate composed of an DX-8951 derivative (Exatecan) and a maleimide-GGFG peptide linker.</p>Formula:C52H56FN9O13Purity:Min. 95%Molecular weight:1,034.1 g/mol
